Novo Nordisk Faces a Multi-Threaded July: Pill Approval, Medicare Launch, and a Cyber Security Incident
Veröffentlicht: 28.06.2026 um 03:13 Uhr, Redaktion boerse-global.de
June 11 was an unusually busy day for Novo Nordisk. The Danish drugmaker won UK approval for an oral version of Wegovy, but also disclosed a cyberattack that same date. As the company enters July, a suite of catalysts — from Medicare access in the US to a pivotal FDA decision on CagriSema — is converging with operational headwinds.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) cleared a daily Wegovy tablet for adults with a body mass index of 30 or higher, and also for patients with a BMI between 27 and 30 who have weight-related conditions. Asda Online Doctor began taking pre-orders on June 27. The pill is expected to cost more than the injectable form, but its key advantage lies in patient preference: many people avoid injections, leaving a largely untapped market. The approval rests on the OASIS-4 study, though detailed efficacy data from that trial have not yet been released.
In the US, the Medicare Bridge Program kicks off July 1, making GLP-1 drugs available to roughly three million eligible beneficiaries for a maximum of $50 per month. The initiative runs through the end of 2027 and targets patients with specific BMIs, comorbidities, or pre-diabetes. Novo Nordisk currently commands about 60% of the Wegovy market in the US, and the program is expected to provide a direct demand boost. The extent of the impact on revenue and market share will become clearer when the company reports second-quarter earnings on August 5.
The same day as the UK pill approval, Novo Nordisk suffered a cyber intrusion. Hackers accessed internal systems and obtained personal data. Two groups — FulcrumSec and TheUSERS007 — tried to extort the company for $25 million and $50 million respectively. Novo Nordisk declined to pay. The compromised data included pseudonymized patient information from clinical trials (participation records, biomarkers, health values, lifestyle factors) and more directly identifiable data for doctors and nurses, such as names, registration numbers, email addresses, and phone numbers. The company said core operations remain unaffected and external cybersecurity experts are assisting with the investigation.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The pipeline is also moving. Novo Nordisk has registered a new study for Cagrilintid, targeting patients who cannot tolerate GLP-1 therapies due to gastrointestinal side effects, with safety and tolerability as the primary endpoint. The trial started in May 2026 and plans roughly eight months of treatment per participant. At the ISTH Congress in Paris from July 11 to 15, the company will present new data on Denecimig, a bispecific antibody designed to prevent bleeding episodes in hemophilia A; its FDA application has been under review since September 2025. The most critical regulatory milestone remains CagriSema, for which Novo filed a New Drug Application with the FDA in December 2025. A decision is expected in the fourth quarter of 2026. The Phase 3 REIMAGINE program delivered significant reductions in HbA1c and body weight, with all three studies meeting their primary endpoints.
Analyst views on the stock are mixed. Goldman Sachs nudged its price target up to 310 Danish kroner but maintained a Neutral rating. Morningstar downgraded Novo from Buy to Hold, assigning a fair value of 343 kroner — still well above the current price. Deutsche Bank had earlier in June set a Hold rating with a target of 290 kroner. The divergence highlights genuine disagreement over the sustainability of growth in the obesity and diabetes markets.
Not all GLP-1 markets are humming. In India, demand for generic GLP-1 preparations is cooling sharply, with producers slashing sales targets by 25% to 30%. Doctors remain cautious and patient adherence is low. Local health experts are also warning against long-term use of GLP-1 drugs in people who have neither diabetes nor clinical obesity. While this does not directly affect Novo Nordisk, it underscores that the global growth narrative is uneven.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The stock closed the latest week at €42.19, a gain of roughly 8.5% in seven days and nearly 10% over the past month. That puts it comfortably above its 50-day moving average of €37.80, but still about 31% below the 52-week high of €61.20 from July 2025. The 14-day relative strength index of 71.3 signals that the shares have entered overbought territory in the short term. Anyone buying ahead of the August 5 report is doing so after a significant recovery run — and with the cyberattack investigation still unresolved and the CagriSema clock ticking.
Ad
Novo Nordisk Stock: New Analysis - 28 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
